GGrantIndex
← Leaderboards

Daniela Annenelie Bota

University Of California-Irvine

$3,732,045
Attributed
$6,597,714
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY201125
$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,597,714 · 3

By mechanism

R01$5,731,338 · 2
K08$866,376 · 1

Top collaborators

Most similar at University Of California-Irvine

Same institution · by research overlap

Others in their field

Top investigators on “Mitochondria

Research focus

MitochondriaClinical TrialsMitochondrial DnaIn VivoIn VitroChemotherapyMalignant NeoplasmsChemotherapeutic AgentBrainNovel TherapeuticsBioenergeticsSmall Interfering RnaPathway InteractionsToxic EffectMolecularFda ApprovedNovel StrategiesCell LineInhibitorDensityDendritic SpinesDiagnosisCancer PatientAdverse Effects

Grant awards (25)

Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$601,825
R01 · FY2025 · CA · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$82,514
R01 · FY2025 · CA · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$80,303
R01 · FY2025 · CA · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$574,826
R01 · FY2024 · CA · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$399,338
R01 · FY2024 · NS · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$95,469
R01 · FY2024 · CA · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$82,514
R01 · FY2024 · CA · contact PI
Supplement to Promote Diversity: Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$33,139
R01 · FY2024 · CA · contact PI
Supplement to Promote Diversity:Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$18,319
R01 · FY2024 · CA · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$9,145
R01 · FY2024 · NS · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$613,079
R01 · FY2023 · CA · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$411,688
R01 · FY2023 · NS · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$78,339
R01 · FY2023 · NS · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$616,655
R01 · FY2022 · CA · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$411,688
R01 · FY2022 · NS · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$78,339
R01 · FY2022 · NS · contact PI
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system$634,722
R01 · FY2021 · CA · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$411,688
R01 · FY2021 · NS · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$71,810
R01 · FY2021 · NS · contact PI
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma$425,938
R01 · FY2020 · NS · contact PI
Mechanisms of Chemotherapy Induced Cognitive Defects$175,068
K08 · FY2015 · NS · contact PI
Mechanisms of Chemotherapy Induced Cognitive Defects$175,068
K08 · FY2014 · NS · contact PI
Mechanisms of Chemotherapy Induced Cognitive Defects$175,068
K08 · FY2013 · NS · contact PI
Mechanisms of Chemotherapy Induced Cognitive Defects$170,586
K08 · FY2012 · NS · contact PI
Mechanisms of Chemotherapy Induced Cognitive Defects$170,586
K08 · FY2011 · NS · contact PI